Single-dose ciprofloxacin for shigellosis in adults

Sk, Bhattacharya; Mk, Bhattacharya; Dutta, D; Dutta, P; Paul, Mousumi; Sen, D.; Sarkar, S.; Saha, Ananda Kumar; Pal, S. C.

doi:10.1016/0163-4453(92)93849-l

Cited by 5 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…norfloxacin or ciprofloxacin) were found to be highly effective against multiresistant strains of Shigella. Thereafter, norfloxacin has become the drug of choice for the treatment of shigellosis (8,9). Moreover, Shigella strains require two consecutive mutations to develop resistance against a fluorinated quinolone, whereas only one mutation is sufficient to develop resistance to nonfluorinated quinolones.…”

Section: Parametersmentioning

confidence: 99%

Double‐blind, randomized clinical trial for safety and efficacy of norfloxacin for shigellosis in children

Sk¹,

Dutta

et al. 1997

Acta Paediatrica

View full text Add to dashboard Cite

In a randomized, double-blind clinical trial, the efficacy and safety of norfloxacin were compared with nalidixic acid in the treatment of shigellosis in children. Out of 59 cases, Shigella spp. were isolated from 8 cases in the nalidixic acid group and 14 cases in the norfloxacin group. The norfloxacin group had significantly less duration of diarrhoea and presence of blood in stool as compared to the nalidixic acid group. No joint problem was encountered in this study at up to 4 months follow-up. Norfloxacin is safe and effective and showed no cartilage toxicity on short-term follow-up.

show abstract

Section: Parametersmentioning

confidence: 99%

Double‐blind, randomized clinical trial for safety and efficacy of norfloxacin for shigellosis in children

Sk¹,

Dutta

et al. 1997

Acta Paediatrica

View full text Add to dashboard Cite

show abstract

Resistant Gut Bacteria

Threlfall¹

2009

Manson's Tropical Diseases

View full text Add to dashboard Cite

Consensus Report on Shigella Controlled Human Infection Model: Conduct of Studies

Talaat

Bourgeois

Frenck

et al. 2019

Clinical Infectious Diseases

View full text Add to dashboard Cite

Shigella causes morbidity and mortality worldwide, primarily affecting young children living in low-resource settings. It is also of great concern due to increasing antibiotic resistance, and is a priority organism for the World Health Organization. A Shigella vaccine would decrease the morbidity and mortality associated with shigellosis, improve child health, and decrease the need for antibiotics. Controlled human infection models (CHIMs) are useful tools in vaccine evaluation for early up- or down-selection of vaccine candidates and potentially useful in support of licensure. Over time, the methods employed in these models have become more uniform across sites performing CHIM trials, although some differences in conduct persist. In November 2017, a Shigella CHIM workshop was convened in Washington, District of Columbia. Investigators met to discuss multiple aspects of these studies, including study procedures, clinical and immunological endpoints, and shared experiences. This article serves as a uniform procedure by which to conduct Shigella CHIM studies.

show abstract

Single-dose ciprofloxacin for shigellosis in adults

Cited by 5 publications

References 5 publications

Double‐blind, randomized clinical trial for safety and efficacy of norfloxacin for shigellosis in children

Double‐blind, randomized clinical trial for safety and efficacy of norfloxacin for shigellosis in children

Resistant Gut Bacteria

Consensus Report on Shigella Controlled Human Infection Model: Conduct of Studies

Contact Info

Product

Resources

About